@article{10.37349/ent.2022.00018,
abstract = {Subarachnoid hemorrhage (SAH) has deleterious outcomes for patients, and during the hospital stay, patients are susceptible to vasospasm and delayed cerebral ischemia. Coronavirus disease 2019 (COVID-19) has been shown to worsen hypertension through angiotensin-converting enzyme 2 (ACE2) activity, therefore, predisposing to aneurysm rupture. The classic renin-angiotensin pathway activation also predisposes to vasospasm and subsequent delayed cerebral ischemia. Matrix metalloproteinase 9 upregulation can lead to an inflammatory surge, which worsens outcomes for patients. SAH patients with COVID-19 are more susceptible to ventilator-associated pneumonia, reversible cerebral vasoconstriction syndrome, and respiratory distress. Emerging treatments are warranted to target key components of the anti-inflammatory cascade. The aim of this review is to explore how the COVID-19 virus and the intensive care unit (ICU) treatment of severe COVID can contribute to SAH.},
author = {Panther, Eric J and Lucke-wold, Brandon},
doi = {10.37349/ent.2022.00018},
journal = {Exploration of Neuroprotective Therapy},
pages = {65--73},
title = {{Subarachnoid hemorrhage: management considerations for COVID-19}},
url = {https://www.explorationpub.com/Journals/ent/Article/100418},
volume = {2},
year = {2022}
number = {2}
}